The approval was based on data from the randomized, double-masked phase 3 BALATON (ClinicalTrials.gov Identifier: NCT04740905) and COMINO (ClinicalTrials.gov Identifier: NCT04740931) studies ...

Central retinal vein occlusion (CRVO) is an eye condition that affects a vein in the retina. Learn about symptoms, causes, treatments, and more.

On October 26, 2023, Genentech, a member of the Roche Group, announced that the FDA approved VABYSMO (faricimab-svoa) for the treatment of macular edema following retinal vein occlusion (RVO).

Risk of retinal vein occlusion was higher in the 6 months after infection than in the 6 months prior (adjusted incidence rate ratio [IRR] 1.54, 95% CI 1.05-2.26, P =0.03), according to Bobeck ...

11. more visual fields are done because some patients who cannot tolerate visual fields with an eye patch tolerated the no-patch method; and 12. patients preferred using no eye patch.

The primary efficacy endpoint was the change in BCVA from baseline to 24 weeks, which tarcocimab demonstrated in those with branch retinal vein occlusion (P = .0004) and in the overall RVO ...

They are an extended look at patients who received Vabysmo from the phase 3 BALATON and COMINO studies, which compared Roche’s drug to Eylea in branch and central retinal vein occlusion (BRVO ...

Appraisal Committee members The Appraisal Committees are standing advisory committees of NICE. Members are appointed for a 3-year term. A list of the Committee members who took part in the discussions ...

Inflammation in Retinal Vein Occlusion. International Journal of Inflammation. 2013; 2013:438412. xi Aodishi® (OZURDEX®) (Package Insert) Shanghai, China, Allergan PLC, Dublin Ireland 2017 ...